> Pharmaceutical Litigation > Telaprevir
Telaprevir, sold under the brand name Incivek, is prescribed along with its partner drugs peginterferon and ribavirin to treat hepatitis C. Approved in May 2011, Incivek has been implicated in several deaths from severe skin reactions.
In December 2012, The FDA issued a safety warning and requested that a black box warning be added to the label of Incivek. A black box warning is the FDA’s highest level of warning and is used only when a drug has significant risk of serious effects.
Serious skin reactions that may be caused by telaprevir include:
These skin conditions are not simple rashes, but seriously debilitating and life-threatening reactions. The seriousness of the risk associated with telaprevir was not revealed for the first year and a half the drug was on the market. Because they were not properly warned of the risks, patients continued treatment after skin conditions presented themselves and lost their lives.
The attorneys at the Law Offices of Brian D. Witzer are committed to seeking justice and compensation for the victims of telaprevir and their families. If you or a loved one was injured by telaprevir, contact us by calling (888) WITZER-6 for a free, no-obligation consultation.